<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report"><front><journal-meta><journal-id journal-id-type="nlm-ta">Dermatol Ther (Heidelb)</journal-id><journal-id journal-id-type="iso-abbrev">Dermatol Ther (Heidelb)</journal-id><journal-title-group><journal-title>Dermatology and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8210</issn><issn pub-type="epub">2190-9172</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27714595</article-id><article-id pub-id-type="pmc">5120636</article-id><article-id pub-id-type="publisher-id">147</article-id><article-id pub-id-type="doi">10.1007/s13555-016-0147-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Stein Gold</surname><given-names>Linda</given-names></name><address><email>lstein1@hfhs.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Villumsen</surname><given-names>John</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rosen</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Henry Ford Health System, Detroit, MI USA </aff><aff id="Aff2"><label>2</label>LEO Pharma A/S, Ballerup, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2016</year></pub-date><volume>6</volume><issue>4</issue><fpage>667</fpage><lpage>673</lpage><history><date date-type="received"><day>23</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>© The Author(s) 2016</copyright-statement></permissions><abstract id="Abs1"><sec><title><offsets xml_i="2407" xml_f="2419" txt_i="11" txt_f="23">Introduction</offsets></title><p><offsets xml_i="2430" xml_f="3043" txt_i="24" txt_f="637">Good treatment adherence is important in the effective management of psoriasis and is related to both the frequency of applications and the amount of product used versus the recommended dose. The efficacy and safety of fixed combination calcipotriol 50 µg/g (Cal) and betamethasone 0.5 mg/g as dipropionate (BD) in the treatment of psoriasis is well established; an aerosol foam formulation has been developed to enhance adherence. This subanalysis from the Phase III PSO-FAST study evaluates the amount of Cal/BD foam used during treatment and the association between the extent and severity of baseline disease.</offsets></p></sec><sec><title><offsets xml_i="3065" xml_f="3072" txt_i="639" txt_f="646">Methods</offsets></title><p><offsets xml_i="3083" xml_f="3602" txt_i="647" txt_f="1166">Patients (≥18 years) with mild-to-severe body psoriasis were randomized 3:1 to once-daily Cal/BD foam or vehicle. The amount of Cal/BD foam and vehicle used over the 4-week study period was evaluated according to three baseline disease assessments: extent of body surface area (BSA) affected by psoriasis, physician’s global assessment of disease severity (PGA) and modified psoriasis area and severity index (mPASI). Treatment success and mPASI75 rates were assessed according to body mass index (BMI) and body weight.</offsets></p></sec><sec><title><offsets xml_i="3624" xml_f="3631" txt_i="1168" txt_f="1175">Results</offsets></title><p><offsets xml_i="3642" xml_f="3772" txt_i="1176" txt_f="1306">323 patients were randomized to Cal/BD foam and 103 to vehicle. At week 4, the mean total amount of Cal/BD foam used was 120.8 g (</offsets><italic><offsets xml_i="3780" xml_f="3781" txt_i="1306" txt_f="1307">n</offsets></italic><offsets xml_i="3790" xml_f="3857" txt_i="1307" txt_f="1374"> = 293), which was similar to the amount of vehicle used (128.9 g; </offsets><italic><offsets xml_i="3865" xml_f="3866" txt_i="1374" txt_f="1375">n</offsets></italic><offsets xml_i="3875" xml_f="4268" txt_i="1375" txt_f="1768"> = 98). The total amount of Cal/BD foam used at week 4 was greater with increasing BSA and increasing severity of baseline PGA and mPASI. Throughout the study, 93.1% of patients in the Cal/BD foam group and 99.0% of patients in the vehicle group missed ≤10% of treatment applications. Treatment success and mPASI75 rates were generally similar when stratified according to BMI and body weight.</offsets></p></sec><sec><title><offsets xml_i="4290" xml_f="4301" txt_i="1770" txt_f="1781">Conclusions</offsets></title><p><offsets xml_i="4312" xml_f="4495" txt_i="1782" txt_f="1965">This subanalysis demonstrates that Cal/BD aerosol foam is used appropriately and is effective for the treatment of psoriasis, independent of BMI and the extent or severity of disease.</offsets></p></sec><sec><title><offsets xml_i="4517" xml_f="4539" txt_i="1967" txt_f="1989">Clinical trials number</offsets></title><p><offsets xml_i="4550" xml_f="4562" txt_i="1990" txt_f="2002">NCT01866163.</offsets></p></sec><sec><title><offsets xml_i="4584" xml_f="4591" txt_i="2004" txt_f="2011">Funding</offsets></title><p><offsets xml_i="4602" xml_f="4617" txt_i="2012" txt_f="2027">LEO Pharma A/S.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Calcipotriol</kwd><kwd>Betamethasone dipropionate</kwd><kwd>Aerosol foam</kwd><kwd>Psoriasis</kwd><kwd>Body mass index</kwd><kwd>Body surface area</kwd><kwd>Severity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer Healthcare 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="5090" xml_f="5102" txt_i="2036" txt_f="2048">Introduction</offsets></title><p><offsets xml_i="5113" xml_f="5208" txt_i="2049" txt_f="2144">Therapeutic guidelines for psoriasis recommend the topical use of corticosteroids and vitamin D</offsets><sub><offsets xml_i="5213" xml_f="5214" txt_i="2144" txt_f="2145">3</offsets></sub><offsets xml_i="5220" xml_f="5335" txt_i="2145" txt_f="2260"> analogs as first-line treatment, either as separate products (used together) or as a fixed combination treatment [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="5367" xml_f="5368" txt_i="2260" txt_f="2261">1</offsets></xref><offsets xml_i="5375" xml_f="5515" txt_i="2261" txt_f="2401">]. Treatment adherence has been recognized as an important issue in the management of chronic inflammatory skin diseases such as psoriasis [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="5547" xml_f="5548" txt_i="2401" txt_f="2402">2</offsets></xref><offsets xml_i="5555" xml_f="5636" txt_i="2402" txt_f="2483">]. Although many patients can manage their psoriasis with topical therapy alone [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="5668" xml_f="5669" txt_i="2483" txt_f="2484">1</offsets></xref><offsets xml_i="5676" xml_f="5678" txt_i="2484" txt_f="2486">, </offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="5710" xml_f="5711" txt_i="2486" txt_f="2487">3</offsets></xref><offsets xml_i="5718" xml_f="5720" txt_i="2487" txt_f="2489">, </offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="5752" xml_f="5753" txt_i="2489" txt_f="2490">4</offsets></xref><offsets xml_i="5760" xml_f="6142" txt_i="2490" txt_f="2872">], adherence remains a significant issue. Adherence is related to both the frequency of applications and the amount of product used compared with the recommended dose; a systematic literature review found that the frequency of topical treatment application in randomized controlled trials ranged from 55% to 100%, while patients applied between 35% and 72% of the recommended dose [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="6174" xml_f="6175" txt_i="2872" txt_f="2873">2</offsets></xref><offsets xml_i="6182" xml_f="6365" txt_i="2873" txt_f="3056">]. A number of reasons for poor adherence to topical therapy were identified, including a lack of efficacy, excessive time applying the medication, and poor cosmetic characteristics [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="6397" xml_f="6398" txt_i="3056" txt_f="3057">2</offsets></xref><offsets xml_i="6405" xml_f="6497" txt_i="3057" txt_f="3149">]. Adherence was shown to be greater for once-daily treatment as compared with twice daily [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="6529" xml_f="6530" txt_i="3149" txt_f="3150">2</offsets></xref><offsets xml_i="6537" xml_f="6619" txt_i="3150" txt_f="3232">]. Studies have also shown that the topical vehicle used can impact on adherence [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="6651" xml_f="6652" txt_i="3232" txt_f="3233">5</offsets></xref><offsets xml_i="6659" xml_f="6661" txt_i="3233" txt_f="3235">, </offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="6693" xml_f="6694" txt_i="3235" txt_f="3236">6</offsets></xref><offsets xml_i="6701" xml_f="6807" txt_i="3236" txt_f="3342">]; patients generally prefer a vehicle that is simple and fast to apply, quickly absorbed and not greasy [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="6839" xml_f="6840" txt_i="3342" txt_f="3343">7</offsets></xref><offsets xml_i="6847" xml_f="6849" txt_i="3343" txt_f="3345">].</offsets></p><p><offsets xml_i="6856" xml_f="7023" txt_i="3346" txt_f="3513">The efficacy and safety of the fixed combination of calcipotriol 50 µg/g (Cal) and betamethasone 0.5 mg/g as dipropionate (BD) has been confirmed in long-term trials [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="7055" xml_f="7056" txt_i="3513" txt_f="3514">8</offsets></xref><offsets xml_i="7063" xml_f="7064" txt_i="3514" txt_f="3515">–</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="7097" xml_f="7099" txt_i="3515" txt_f="3517">11</offsets></xref><offsets xml_i="7106" xml_f="7222" txt_i="3517" txt_f="3633">]. The ointment and gel formulations of this fixed combination are established first-line treatments for psoriasis [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="7255" xml_f="7257" txt_i="3633" txt_f="3635">12</offsets></xref><offsets xml_i="7264" xml_f="7543" txt_i="3635" txt_f="3914">]. An aerosol foam formulation of the fixed Cal/BD combination has been developed to enhance adherence and increase the therapeutic options available to patients. Previous Cal/BD aerosol foam studies have shown greater in vitro skin penetration compared with other formulations [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="7576" xml_f="7578" txt_i="3914" txt_f="3916">13</offsets></xref><offsets xml_i="7585" xml_f="7686" txt_i="3916" txt_f="4017">], and a significantly greater anti-psoriatic effect over 4 weeks of treatment than Cal/BD ointment [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="7719" xml_f="7721" txt_i="4017" txt_f="4019">14</offsets></xref><offsets xml_i="7728" xml_f="7730" txt_i="4019" txt_f="4021">, </offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="7763" xml_f="7765" txt_i="4021" txt_f="4023">15</offsets></xref><offsets xml_i="7772" xml_f="7780" txt_i="4023" txt_f="4031">], gel [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="7813" xml_f="7815" txt_i="4031" txt_f="4033">16</offsets></xref><offsets xml_i="7822" xml_f="7860" txt_i="4033" txt_f="4071">], and individual active ingredients [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="7893" xml_f="7895" txt_i="4071" txt_f="4073">17</offsets></xref><offsets xml_i="7902" xml_f="7945" txt_i="4073" txt_f="4116">], with a comparable tolerability profile [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="7978" xml_f="7980" txt_i="4116" txt_f="4118">15</offsets></xref><offsets xml_i="7987" xml_f="7988" txt_i="4118" txt_f="4119">–</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="8021" xml_f="8023" txt_i="4119" txt_f="4121">17</offsets></xref><offsets xml_i="8030" xml_f="8250" txt_i="4121" txt_f="4341">]. In a large, double-blind, Phase III, 4-week study in patients with psoriasis vulgaris (PSO-FAST [NCT01866163]), treatment with Cal/BD aerosol foam led to significantly greater treatment success rates (53.3% vs. 4.8%; </offsets><italic><offsets xml_i="8258" xml_f="8259" txt_i="4341" txt_f="4342">P</offsets></italic><offsets xml_i="8268" xml_f="8375" txt_i="4342" txt_f="4446"> &lt; 0.001) and lower mean modified psoriasis area and severity index (mPASI; excluding head; 2.0 vs 5.5; </offsets><italic><offsets xml_i="8383" xml_f="8384" txt_i="4446" txt_f="4447">P</offsets></italic><offsets xml_i="8393" xml_f="8449" txt_i="4447" txt_f="4500"> &lt; 0.001) scores compared with aerosol foam vehicle [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="8482" xml_f="8484" txt_i="4500" txt_f="4502">18</offsets></xref><offsets xml_i="8491" xml_f="8493" txt_i="4502" txt_f="4504">].</offsets></p><p><offsets xml_i="8500" xml_f="8707" txt_i="4505" txt_f="4712">This subanalysis from the PSO-FAST study evaluates the amount of Cal/BD aerosol foam used during treatment and the association between the extent and severity of baseline disease, in patients with psoriasis.</offsets></p></sec><sec id="Sec2"><title><offsets xml_i="8739" xml_f="8746" txt_i="4714" txt_f="4721">Methods</offsets></title><sec id="Sec3"><title><offsets xml_i="8776" xml_f="8801" txt_i="4722" txt_f="4747">Patients and Study Design</offsets></title><p><offsets xml_i="8812" xml_f="9165" txt_i="4748" txt_f="5101">Patients eligible for inclusion in the PSO-FAST study were ≥18 years of age with a clinical diagnosis of mild-to-severe body psoriasis. Patients had between 2% and 30% of their body surface area (BSA; i.e., trunk and limbs) affected by the disease, with an mPASI score of ≥2. Full inclusion and exclusion criteria have been reported in Leonardi et al. [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="9198" xml_f="9200" txt_i="5101" txt_f="5103">18</offsets></xref><offsets xml_i="9207" xml_f="9209" txt_i="5103" txt_f="5105">].</offsets></p><p><offsets xml_i="9216" xml_f="9486" txt_i="5106" txt_f="5376">PSO-FAST (Cal/BD aerosol foam in PSOriasis vulgaris, a Four-week, vehicle-controlled, efficacy And Safety Trial) was a Phase III, multicenter, double-blind study. Patients were randomized (3:1) to Cal/BD aerosol foam or aerosol foam vehicle once daily for up to 4 weeks.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="9518" xml_f="9529" txt_i="5378" txt_f="5389">Assessments</offsets></title><p><offsets xml_i="9540" xml_f="10146" txt_i="5390" txt_f="5981">The total amount of Cal/BD foam used by each patient during the 4-week study was determined by calculating the difference between the weight of the cans dispensed and the weight of the returned cans, multiplied by a correction factor of 0.41 to account for the propellant gases. Adherence was assessed by calculating the percentage of missed treatment applications (≤10%, &gt;10–≤20%, &gt;20–≤30%, &gt;30–≤40%, &gt;40–≤50% and &gt;50%), as follows: the number of applications of Cal/BD foam missed for a particular visit interval was divided by the total number of days for the interval, multiplied by 100.</offsets></p><p><offsets xml_i="10153" xml_f="10497" txt_i="5982" txt_f="6326">Treatment success was defined as the proportion of patients who were clear or almost clear of disease with at least a two-step improvement at week 4, according to the physician’s global assessment of disease severity (PGA). The rate of treatment success was the primary endpoint of the study and the data have been reported in Leonardi et al. [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="10530" xml_f="10532" txt_i="6326" txt_f="6328">18</offsets></xref><offsets xml_i="10539" xml_f="10541" txt_i="6328" txt_f="6330">].</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="10573" xml_f="10581" txt_i="6332" txt_f="6340">Analysis</offsets></title><p><offsets xml_i="10592" xml_f="10918" txt_i="6341" txt_f="6667">The total amount of Cal/BD foam used during the study was evaluated according to three baseline disease assessments: the extent to which a patient’s BSA was affected by psoriasis vulgaris; PGA; and mPASI. The proportion of patients achieving treatment success was stratified according to body weight and body mass index (BMI).</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="10950" xml_f="10983" txt_i="6669" txt_f="6702">Compliance with Ethics Guidelines</offsets></title><p><offsets xml_i="10994" xml_f="11343" txt_i="6703" txt_f="7052">The institutional review boards of all investigational sites approved the protocol. This study was conducted according to Good Clinical Practice guidelines and the principles of the Declaration of Helsinki 1964, as revised in 2013. All patients provided written informed consent prior to enrollment. The ClinicalTrials.gov identifier is NCT01866163.</offsets></p></sec></sec><sec id="Sec7"><title><offsets xml_i="11381" xml_f="11388" txt_i="7055" txt_f="7062">Results</offsets></title><p><offsets xml_i="11399" xml_f="11607" txt_i="7063" txt_f="7271">In total, 323 patients were randomized to Cal/BD foam and 103 to vehicle; 313 (96.9%) and 99 (96.1%) patients, respectively, completed the study. Of the 14 patients who withdrew, eight were lost to follow-up.</offsets></p><p><offsets xml_i="11614" xml_f="11728" txt_i="7272" txt_f="7386">The overall mean (±standard deviation) total amount of Cal/BD aerosol foam used after 4 weeks was 120.8 ± 85.7 g (</offsets><italic><offsets xml_i="11736" xml_f="11737" txt_i="7386" txt_f="7387">n</offsets></italic><offsets xml_i="11746" xml_f="11848" txt_i="7387" txt_f="7489"> = 293/323), which was similar to the mean total amount of aerosol foam vehicle used (128.9 ± 92.9 g; </offsets><italic><offsets xml_i="11856" xml_f="11857" txt_i="7489" txt_f="7490">n</offsets></italic><offsets xml_i="11866" xml_f="12188" txt_i="7490" txt_f="7812"> = 98/103). The mean amount of drug used per week was also similar between treatment groups: Cal/BD aerosol foam 29.8 g/week, vehicle 32.1 g/week. The mean amount of Cal/BD aerosol foam used was consistent from baseline to week 1 (29.9 g/week), from week 1 to week 2 (28.5 g/week), and from week 2 to week 4 (30.2 g/week).</offsets></p><p><offsets xml_i="12195" xml_f="12338" txt_i="7813" txt_f="7956">The total amount of Cal/BD aerosol foam used at week 4 was greater with increasing BSA and increasing severity of baseline PGA and mPASI (Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="12370" xml_f="12371" txt_i="7956" txt_f="7957">1</offsets></xref><offsets xml_i="12378" xml_f="12473" txt_i="7957" txt_f="8052">a–c). Most patients enrolled in the PSO-FAST study had ≤10% of their BSA involved at baseline (</offsets><italic><offsets xml_i="12481" xml_f="12482" txt_i="8052" txt_f="8053">n</offsets></italic><offsets xml_i="12491" xml_f="12591" txt_i="8053" txt_f="8153"> = 227), and used on average between 88.3 and 117.6 g of Cal/BD aerosol foam during treatment (Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="12623" xml_f="12624" txt_i="8153" txt_f="8154">1</offsets></xref><offsets xml_i="12631" xml_f="12807" txt_i="8154" txt_f="8330">a). Throughout the 4-week treatment period, 93.1% of patients in the Cal/BD aerosol foam group and 99.0% of patients in the vehicle group missed ≤10% of treatment applications.</offsets><fig id="Fig1"><label><offsets xml_i="12829" xml_f="12835" txt_i="8330" txt_f="8336">Fig. 1</offsets></label><caption><p><offsets xml_i="12855" xml_f="12923" txt_i="8336" txt_f="8404">Mean total amount of Cal/BD aerosol foam used at week 4 by baseline </offsets><bold><offsets xml_i="12929" xml_f="12930" txt_i="8404" txt_f="8405">a</offsets></bold><offsets xml_i="12937" xml_f="12943" txt_i="8405" txt_f="8411"> BSA; </offsets><bold><offsets xml_i="12949" xml_f="12950" txt_i="8411" txt_f="8412">b</offsets></bold><offsets xml_i="12957" xml_f="12967" txt_i="8412" txt_f="8422"> PGA; and </offsets><bold><offsets xml_i="12973" xml_f="12974" txt_i="8422" txt_f="8423">c</offsets></bold><offsets xml_i="12981" xml_f="12989" txt_i="8423" txt_f="8431"> mPASI. </offsets><italic><offsets xml_i="12997" xml_f="12999" txt_i="8431" txt_f="8433">BD</offsets></italic><offsets xml_i="13008" xml_f="13049" txt_i="8433" txt_f="8474"> betamethasone 0.5 mg/g as dipropionate, </offsets><italic><offsets xml_i="13057" xml_f="13060" txt_i="8474" txt_f="8477">BSA</offsets></italic><offsets xml_i="13069" xml_f="13089" txt_i="8477" txt_f="8497"> body surface area, </offsets><italic><offsets xml_i="13097" xml_f="13100" txt_i="8497" txt_f="8500">Cal</offsets></italic><offsets xml_i="13109" xml_f="13132" txt_i="8500" txt_f="8523"> calcipotriol 50 µg/g, </offsets><italic><offsets xml_i="13140" xml_f="13145" txt_i="8523" txt_f="8528">mPASI</offsets></italic><offsets xml_i="13154" xml_f="13199" txt_i="8528" txt_f="8573"> modified psoriasis area and severity index, </offsets><italic><offsets xml_i="13207" xml_f="13210" txt_i="8573" txt_f="8576">PGA</offsets></italic><offsets xml_i="13219" xml_f="13271" txt_i="8576" txt_f="8628"> physician’s global assessment of disease severity, </offsets><italic><offsets xml_i="13279" xml_f="13281" txt_i="8628" txt_f="8630">SD</offsets></italic><offsets xml_i="13290" xml_f="13309" txt_i="8630" txt_f="8649"> standard deviation</offsets></p></caption><graphic xlink:href="13555_2016_147_Fig1_HTML" id="MO1"></graphic></fig><offsets xml_i="13395" xml_f="13396" txt_i="8650" txt_f="8651">
</offsets></p><p><offsets xml_i="13403" xml_f="13492" txt_i="8652" txt_f="8741">Treatment success rates were generally similar irrespective of body weight and BMI (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="13524" xml_f="13525" txt_i="8741" txt_f="8742">2</offsets></xref><offsets xml_i="13532" xml_f="13752" txt_i="8742" txt_f="8962">a, b). Similarly, additional evaluation of mPASI75 rates (i.e., the proportion of patients who achieved a 75% decrease in mPASI) did not demonstrate a difference in response according body weight or BMI (data not shown).</offsets><fig id="Fig2"><label><offsets xml_i="13774" xml_f="13780" txt_i="8962" txt_f="8968">Fig. 2</offsets></label><caption><p><offsets xml_i="13800" xml_f="13974" txt_i="8968" txt_f="9142">Treatment success (defined as the proportion of patients who were clear or almost clear of disease with at least a two-step improvement at week 4, according to PGA) rates by </offsets><bold><offsets xml_i="13980" xml_f="13981" txt_i="9142" txt_f="9143">a</offsets></bold><offsets xml_i="13988" xml_f="14005" txt_i="9143" txt_f="9160"> body weight and </offsets><bold><offsets xml_i="14011" xml_f="14012" txt_i="9160" txt_f="9161">b</offsets></bold><offsets xml_i="14019" xml_f="14025" txt_i="9161" txt_f="9167"> BMI. </offsets><italic><offsets xml_i="14033" xml_f="14036" txt_i="9167" txt_f="9170">BMI</offsets></italic><offsets xml_i="14045" xml_f="14063" txt_i="9170" txt_f="9188"> body mass index, </offsets><italic><offsets xml_i="14071" xml_f="14074" txt_i="9188" txt_f="9191">PGA</offsets></italic><offsets xml_i="14083" xml_f="14135" txt_i="9191" txt_f="9243"> physician’s global assessment of disease severity, </offsets><italic><offsets xml_i="14143" xml_f="14145" txt_i="9243" txt_f="9245">SE</offsets></italic><offsets xml_i="14154" xml_f="14169" txt_i="9245" txt_f="9260"> standard error</offsets></p></caption><graphic xlink:href="13555_2016_147_Fig2_HTML" id="MO2"></graphic></fig><offsets xml_i="14255" xml_f="14256" txt_i="9261" txt_f="9262">
</offsets></p></sec><sec id="Sec8"><title><offsets xml_i="14288" xml_f="14298" txt_i="9264" txt_f="9274">Discussion</offsets></title><p><offsets xml_i="14309" xml_f="14891" txt_i="9275" txt_f="9854">In the Phase III PSO-FAST study, most patients had mild-to-moderate disease severity (BSA &lt;10%) and, on average, used 88–118 g of Cal/BD foam. The amount of Cal/BD aerosol foam used was comparable to vehicle and the product was used consistently throughout the 4-week study, suggesting that treatment persistence with the foam was good. In addition, patients used an appropriate amount of Cal/BD aerosol foam for the extent and severity of their psoriasis at baseline, since the mean total amount of Cal/BD aerosol foam used increased with increasing baseline BSA, PGA and mPASI.</offsets></p><p><offsets xml_i="14898" xml_f="15125" txt_i="9855" txt_f="10082">The primary analysis demonstrated that significantly more patients using Cal/BD foam achieved treatment success versus vehicle and mean mPASI score was significantly lower for patients using Cal/BD foam than vehicle at week 4 [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="15158" xml_f="15160" txt_i="10082" txt_f="10084">18</offsets></xref><offsets xml_i="15167" xml_f="15583" txt_i="10084" txt_f="10500">]. This subanalysis shows that the effectiveness of Cal/BD aerosol foam, based on treatment success rates, was not affected by body weight or BMI, so can be used in all patients irrespective of their size or extent of their BSA that is covered with plaques (as long as it is within the approved label). It has previously been suggested that BMI may be a prognostic factor for the response to treatment in psoriasis [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="15616" xml_f="15618" txt_i="10500" txt_f="10502">19</offsets></xref><offsets xml_i="15625" xml_f="15773" txt_i="10502" txt_f="10647">]; indeed, a number of studies have shown that some biologic therapies are less effective in patients with a BMI ≥25–30 compared with a BMI &lt;25 [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="15806" xml_f="15808" txt_i="10647" txt_f="10649">19</offsets></xref><offsets xml_i="15815" xml_f="15816" txt_i="10649" txt_f="10650">–</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="15849" xml_f="15851" txt_i="10650" txt_f="10652">23</offsets></xref><offsets xml_i="15858" xml_f="15860" txt_i="10652" txt_f="10654">].</offsets></p><p><offsets xml_i="15867" xml_f="16381" txt_i="10655" txt_f="11169">One limitation of this analysis is that the regular monitoring that occurred during this clinical study of relatively short duration may reinforce patient adherence compared with that observed in the real world. Outside of the clinical trial setting, some patients are unintentionally non-adherent with treatment (e.g., because they forget to use the medication as directed), whilst others are intentionally non-adherent (e.g., altering or stopping treatment because of perceived ineffectiveness or side effects) [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="16414" xml_f="16416" txt_i="11169" txt_f="11171">24</offsets></xref><offsets xml_i="16423" xml_f="16425" txt_i="11171" txt_f="11173">].</offsets></p></sec><sec id="Sec9"><title><offsets xml_i="16457" xml_f="16467" txt_i="11175" txt_f="11185">Conclusion</offsets></title><p><offsets xml_i="16478" xml_f="16700" txt_i="11186" txt_f="11408">In conclusion, this subanalysis from the PSO-FAST study demonstrates that Cal/BD aerosol foam is used appropriately and is effective for the treatment of psoriasis, independent of BMI and the extent or severity of disease.</offsets></p></sec></body><back><fn-group><fn><p><bold>Enhanced content</bold></p><p>To view enhanced content for this article go to <ext-link ext-link-type="uri" xlink:href="http://www.medengine.com/Redeem/D9E6F06027246DA3">http://www.medengine.com/Redeem/D9E6F06027246DA3</ext-link>.</p></fn></fn-group><ack><p>Sponsorship and article processing charges for this study were funded by LEO Pharma A/S. Medical writing support was provided by Andrew Jones PhD, from Mudskipper Business Ltd, funded by LEO Pharma A/S. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.</p><sec id="FPar1"><title>Disclosures</title><p>L. Stein Gold has been a consultant for LEO Pharma A/S and Pfizer, Novartis, Lilly, Galderma, Valeant, Taro, Activis, Allergan, has received honoraria from LEO Pharma A/S and Pfizer, Novartis, Lilly, Galderma, Valeant, Taro, Activis, Allergan, and has participated in speakers’ bureaus for LEO Pharma A/S and Pfizer, Novartis, Lilly, Galderma, Valeant, Taro, Activis, Allergan. J. Villumsen is an employee of LEO Pharma A/S. M. Rosen is an employee of LEO Pharma A/S.</p></sec><sec id="FPar2"><title>Compliance with Ethics Guidelines</title><p>The institutional review boards of all investigational sites approved the protocol. This study was conducted according to Good Clinical Practice guidelines and the principles of the Declaration of Helsinki 1964, as revised in 2013. All patients provided written informed consent prior to enrollment. The ClinicalTrials.gov identifier is NCT01866163.</p></sec><sec id="d30e500"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Korman</surname><given-names>NJ</given-names></name><name><surname>Elmets</surname><given-names>CA</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Gelfand</surname><given-names>JM</given-names></name><name><surname>Gordon</surname><given-names>KB</given-names></name><etal></etal></person-group><article-title>Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</article-title><source>J Am Acad Dermatol</source><year>2009</year><volume>60</volume><fpage>643</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2008.12.032</pub-id><pub-id pub-id-type="pmid">19217694</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaux</surname><given-names>S</given-names></name><name><surname>Castela</surname><given-names>A</given-names></name><name><surname>Archier</surname><given-names>E</given-names></name><name><surname>Gallini</surname><given-names>A</given-names></name><name><surname>Joly</surname><given-names>P</given-names></name><name><surname>Misery</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Adherence to topical treatment in psoriasis: a systematic literature review</article-title><source>J Eur Acad Dermatol Venereol</source><year>2012</year><volume>26</volume><issue>Suppl 3</issue><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1111/j.1468-3083.2012.04525.x</pub-id><pub-id pub-id-type="pmid">22512682</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Ting</surname><given-names>PT</given-names></name><name><surname>Koo</surname><given-names>JY</given-names></name></person-group><article-title>Psoriasis treatment: traditional therapy</article-title><source>Ann Rheum Dis</source><year>2005</year><volume>64</volume><issue>Suppl 2</issue><fpage>ii83</fpage><lpage>ii86</lpage><pub-id pub-id-type="pmid">15708945</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nast</surname><given-names>A</given-names></name><name><surname>Boehncke</surname><given-names>WH</given-names></name><name><surname>Mrowietz</surname><given-names>U</given-names></name><name><surname>Ockenfels</surname><given-names>HM</given-names></name><name><surname>Philipp</surname><given-names>S</given-names></name><name><surname>Reich</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>German S3-guidelines on the treatment of psoriasis vulgaris (short version)</article-title><source>Arch Dermatol Res</source><year>2012</year><volume>304</volume><fpage>87</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1007/s00403-012-1214-8</pub-id><pub-id pub-id-type="pmid">22350179</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puig</surname><given-names>L</given-names></name><name><surname>Carrascosa</surname><given-names>JM</given-names></name><name><surname>Belinchon</surname><given-names>I</given-names></name><name><surname>Fernandez-Redondo</surname><given-names>V</given-names></name><name><surname>Carretero</surname><given-names>G</given-names></name><name><surname>Ruiz-Carrascosa</surname><given-names>JC</given-names></name><etal></etal></person-group><article-title>Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology</article-title><source>Actas Dermosifiliogr.</source><year>2013</year><volume>104</volume><fpage>488</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/j.ad.2012.12.005</pub-id><pub-id pub-id-type="pmid">23395400</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Balkrishnan</surname><given-names>R</given-names></name></person-group><article-title>Topical drug delivery systems in dermatology: a review of patient adherence issues</article-title><source>Expert Opin Drug Deliv</source><year>2012</year><volume>9</volume><fpage>1263</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1517/17425247.2012.711756</pub-id><pub-id pub-id-type="pmid">22861153</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eastman</surname><given-names>WJ</given-names></name><name><surname>Malahias</surname><given-names>S</given-names></name><name><surname>Delconte</surname><given-names>J</given-names></name><name><surname>DiBenedetti</surname><given-names>D</given-names></name></person-group><article-title>Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis</article-title><source>Cutis</source><year>2014</year><volume>94</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">25101344</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kragballe</surname><given-names>K</given-names></name><name><surname>Austad</surname><given-names>J</given-names></name><name><surname>Barnes</surname><given-names>L</given-names></name><name><surname>Bibby</surname><given-names>A</given-names></name><name><surname>de la Brassinne</surname><given-names>M</given-names></name><name><surname>Cambazard</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet<sup>®</sup>/Dovobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris</article-title><source>Dermatology</source><year>2006</year><volume>213</volume><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1159/000096069</pub-id><pub-id pub-id-type="pmid">17135738</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kragballe</surname><given-names>K</given-names></name><name><surname>Austad</surname><given-names>J</given-names></name><name><surname>Barnes</surname><given-names>L</given-names></name><name><surname>Bibby</surname><given-names>A</given-names></name><name><surname>de la Brassinne</surname><given-names>M</given-names></name><name><surname>Cambazard</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris</article-title><source>Br J Dermatol</source><year>2006</year><volume>154</volume><fpage>1155</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2006.07236.x</pub-id><pub-id pub-id-type="pmid">16704648</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>J</given-names></name><name><surname>Hol</surname><given-names>CW</given-names></name><name><surname>Vink</surname><given-names>J</given-names></name></person-group><article-title>Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2015</year><volume>29</volume><fpage>2349</fpage><lpage>2355</lpage><pub-id pub-id-type="doi">10.1111/jdv.13230</pub-id><pub-id pub-id-type="pmid">26337069</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luger</surname><given-names>TA</given-names></name><name><surname>Cambazard</surname><given-names>F</given-names></name><name><surname>Larsen</surname><given-names>FG</given-names></name><name><surname>Bourcier</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Clonier</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis</article-title><source>Dermatology</source><year>2008</year><volume>217</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1159/000155642</pub-id><pub-id pub-id-type="pmid">18787325</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laws</surname><given-names>PM</given-names></name><name><surname>Young</surname><given-names>HS</given-names></name></person-group><article-title>Topical treatment of psoriasis</article-title><source>Expert Opin Pharmacother</source><year>2010</year><volume>11</volume><fpage>1999</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1517/14656566.2010.492778</pub-id><pub-id pub-id-type="pmid">20569091</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Hollesen Basse L, Olesen M, Lacour JP, Queille-Roussel C. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol. 2014;134:S33:abst 192.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Queille-Roussel</surname><given-names>C</given-names></name><name><surname>Olesen</surname><given-names>M</given-names></name><name><surname>Villumsen</surname><given-names>J</given-names></name><name><surname>Lacour</surname><given-names>JP</given-names></name></person-group><article-title>Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris</article-title><source>Clin Drug Investig</source><year>2015</year><volume>35</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1007/s40261-015-0269-7</pub-id><pub-id pub-id-type="pmid">25708531</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>J</given-names></name><name><surname>Tyring</surname><given-names>S</given-names></name><name><surname>Werschler</surname><given-names>WP</given-names></name><name><surname>Bruce</surname><given-names>S</given-names></name><name><surname>Olesen</surname><given-names>M</given-names></name><name><surname>Villumsen</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris—a randomized phase II study</article-title><source>J Dermatol Treat.</source><year>2016</year><volume>27</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.3109/09546634.2015.1083935</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>C</given-names></name><name><surname>Stein Gold</surname><given-names>L</given-names></name><name><surname>Cambazard</surname><given-names>F</given-names></name><name><surname>Kalb</surname><given-names>RE</given-names></name><name><surname>Lowson</surname><given-names>D</given-names></name><name><surname>Bang</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy versus gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study</article-title><source>J Eur Acad Dermatol Venereol.</source><year>2016</year></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Tyring</surname><given-names>S</given-names></name><name><surname>Bukhalo</surname><given-names>M</given-names></name><name><surname>Alonso-Llamazares</surname><given-names>J</given-names></name><name><surname>Olesen</surname><given-names>M</given-names></name><name><surname>Lowson</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase II study</article-title><source>J Clin Aesthet Dermatol</source><year>2016</year><volume>9</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">27313822</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname><given-names>C</given-names></name><name><surname>Bagel</surname><given-names>J</given-names></name><name><surname>Yamauchi</surname><given-names>P</given-names></name><name><surname>Pariser</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Olesen</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris—a randomized phase III study (PSO-FAST)</article-title><source>J Drugs Dermatol</source><year>2015</year><volume>14</volume><fpage>1468</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">26659941</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naldi</surname><given-names>L</given-names></name><name><surname>Addis</surname><given-names>A</given-names></name><name><surname>Chimenti</surname><given-names>S</given-names></name><name><surname>Giannetti</surname><given-names>A</given-names></name><name><surname>Picardo</surname><given-names>M</given-names></name><name><surname>Tomino</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project</article-title><source>Dermatology.</source><year>2008</year><volume>217</volume><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1159/000156599</pub-id><pub-id pub-id-type="pmid">18810241</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassano</surname><given-names>N</given-names></name><name><surname>Galluccio</surname><given-names>A</given-names></name><name><surname>De Simone</surname><given-names>C</given-names></name><name><surname>Loconsole</surname><given-names>F</given-names></name><name><surname>Massimino</surname><given-names>SD</given-names></name><name><surname>Plumari</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data</article-title><source>J Biol Regul Homeost Agents</source><year>2008</year><volume>22</volume><fpage>233</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">19036225</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umezawa</surname><given-names>Y</given-names></name><name><surname>Saeki</surname><given-names>H</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name></person-group><article-title>Some clinical factors affecting quality of the response to ustekinumab for psoriasis</article-title><source>J Dermatol</source><year>2014</year><volume>41</volume><fpage>690</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1111/1346-8138.12538</pub-id><pub-id pub-id-type="pmid">25040159</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanaba</surname><given-names>K</given-names></name><name><surname>Umezawa</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Fukuchi</surname><given-names>O</given-names></name><etal></etal></person-group><article-title>Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients</article-title><source>Arch Dermatol Res</source><year>2014</year><volume>306</volume><fpage>921</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1007/s00403-014-1495-1</pub-id><pub-id pub-id-type="pmid">25193345</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puig</surname><given-names>L</given-names></name></person-group><article-title>Obesity and psoriasis: body weight and body mass index influence the response to biological treatment</article-title><source>J Eur Acad Dermatol Venereol</source><year>2011</year><volume>25</volume><fpage>1007</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1111/j.1468-3083.2011.04065.x</pub-id><pub-id pub-id-type="pmid">21492252</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>HL</given-names></name><name><surname>Fortune</surname><given-names>DG</given-names></name><name><surname>Griffiths</surname><given-names>CE</given-names></name></person-group><article-title>Adherence to treatment in patients with psoriasis</article-title><source>J Eur Acad Dermatol Venereol</source><year>2006</year><volume>20</volume><fpage>370</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1111/j.1468-3083.2006.01565.x</pub-id><pub-id pub-id-type="pmid">16643132</pub-id></element-citation></ref></ref-list></back></article>